Trials / Recruiting
RecruitingNCT03877796
Clinical Pre-screening Protocol for Ovarian Cancer
Development of Drug Response Predictor (DRP) to Test Sensitivity to Investigational Anti-Cancer Drugs in Patients With Advanced Ovarian Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Allarity Therapeutics · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Drug Response Predictor® (DRP) | A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not. |
Timeline
- Start date
- 2019-04-11
- Primary completion
- 2026-09-01
- Completion
- 2026-12-01
- First posted
- 2019-03-18
- Last updated
- 2025-10-30
Locations
5 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03877796. Inclusion in this directory is not an endorsement.